The use of nicotinic acid to treat dyslipidemia is limited by induction of a "flushing" response, mediated in part by the interaction of prostaglandin D 2 (PGD 2 ) with its G-protein coupled receptor DP1 (Ptgdr). The impact of DP1 blockade (genetic or pharmacologic) was assessed in experimental murine models of atherosclerosis. In Ptgdr mice fed a high-fat diet for 8 weeks; however, this effect was not sustained for 16 or 24 weeks.
Antagonist activity at platelet TP was monitored in human platelet assays that measure the inhibition of U46619 (TxA 2 mimetic)-induced platelet aggregation in platelet rich plasma (19) . 
Animals

ApoE
Ldlr -/-
mice used in these studies were bred from strain B6.129-Ldlr tm1Her /J, stock no. 002207, from the Jackson Laboratory. Both the ApoE and the Ldlr knockout mice were backcrossed into C57BL/6 at least ten generations before being used in the study.
Both strains of mice, particularly on a Western diet, were prone to develop skin lesions, which were exacerbated by fighting among cage mates; however, skin lesion development may also be facility-dependent. We excluded animals with large or unhealed lesions (~5% of ApoE knockouts and ~ 15% of Ldlr knockouts) because the presence of these skin lesions is associated with decreased plaque volume (K Cheng, unpublished data), presumably because of the immune responses generated. Mice with small skin lesions that had healed may have been included; however, an attempt was made to closely monitor the mice across the duration of the experiments to minimize this potential variable.
All animals were kept in a controlled environment, with a 12-hour light/dark cycle, with constant temperature and humidity, and had access to food and water ad libitum. The studies were conducted in conformity with the Public Health Service (PHS) Policy on Humane Care and by guest, on October 22, 2017 www.jlr.org
Downloaded from
8
One week prior to performing the vasodilatation/vasoconstriction studies, mice were switched to milled HFWD, which contained an admixture of L-655 at 0 (chow-alone control), 0.003%, 0.01% or 0.03% (w/w). Mice had access to the diets ad libitum.
The first series of studies was performed to test for the lack of TP antagonism in mice fed L-655 for 1 week. To demonstrate that these strains of mice were indeed responsive to TP antagonism, mice that had not been exposed to L-655 were used to monitor the effects of the TP antagonist SQ-29,548 on U46619-induced vasoconstriction. Studies were carried out in the morning, immediately following the end of the feeding cycle (starting at 8:00 AM and not extending past 11:00 AM), when plasma levels of L-655 were expected to be the highest.
To study the effects of L-655 on vasoconstriction, mice were anesthetized with sodium pentobarbital (60 mg/kg, intraperitoneal injection) 10 minutes prior to the start of the vasoconstriction studies. Cutaneous blood flow in the mouse ear was measured by laser Doppler perfusion imaging, employing a PeriScan PIMII laser Doppler Perfusion Imager system (Perimed, Inc., North Royalton, Ohio). The settings of the system were: repeated mode, image size 12 × 12, start method auto interval, 40 images, images every 30 seconds, medium resolution, intensity 7-9V, range 0-3V. All measurements were taken from the ventral side of the right ear.
Mice were placed in left lateral recumbency, and the right ear was taped to a flat surface, exposing the ventral side for measurements. After a 3-minute baseline reading, U46619 (2 mg/kg) or vehicle (5% DMSO in water) was administered by subcutaneous injection, and cutaneous blood perfusion in the ear was measured for another 17 minutes. Perfusion values for the baseline in each animal were averaged and subsequent values after injection of vehicle or U46619 were expressed as the percentage change over this initial value. Negative percentage changes were indicative of reduced blood perfusion (i.e., vasoconstriction). All procedures were by guest, on October 22, 2017 www.jlr.org Downloaded from performed under dim lights. In the control group of animals not exposed to L-655, SQ-29,548 (3 mg/kg) was administered by intraperitoneal injection after a 3-minute baseline reading. Five minutes later, animals were challenged with a subcutaneous dose of U46619 at 2 mg/kg.
Vasoconstriction was then monitored for another 17 minutes.
The second series of studies was designed to determine the minimal dose of L-655 that would inhibit PGD 2 -induced vasodilatation in male and female ApoE -/-or Ldlr -/-mice. Mice were fed the HFWD as described above. One week prior to performing the vasodilatation studies, mice were switched to milled HFWD, which contained an admixture of L-655 at 0 (chow-alone control), 0.003%, 0.1%, or 0.03% (w/w). Mice had access to the diets ad libitum. After feeding on medicated diets for 1 week, the vasodilatatory response to 2 mg/kg PGD 2 was tested in the mice using the same Laser Doppler perfusion technique described above, with the following modifications: on the day of study, mice were placed in clean cages in the morning (between 7:30-8:00 AM), and switched to HFWD lacking L-655 to prevent any further exposure to the compound-containing diet. Vasodilatation was studied in the afternoon (after 3:00 PM), after the medicated diet had been removed for at least 7 hours. Studying vasodilatation in the afternoon, many hours after the last possible dose of compound could be ingested, provided the most stringent test of in vivo DP1 antagonism since this time point likely reflected the minimal plasma concentration of L-655 that would occur when mice were not actively feeding. After a 3-minute baseline reading of cutaneous blood perfusion, PGD 2 (2 mg/kg) or vehicle (0.5% ethanol in saline) were administered by intraperitoneal injection and measurement of cutaneous perfusion continued for another 17 minutes. Perfusion values for the baseline in each animal were averaged and subsequent values after injection of vehicle or PGD 2 were expressed as percent change over by guest, on October 22, 2017 www.jlr.org Downloaded from this initial value. Positive percentage changes were indicative of increased blood perfusion (i.e. vasodilatation).
Treatment groups
Genetic studies
To study the effect of DP1 deficiency on the development of atherosclerosis, parallel To study whether pharmacological antagonism of DP1 had any effect on the development of atherosclerosis or on the anti-atherogenic properties of nicotinic acid in Ldlr -/-mice, a large 3-part study was carried out ( Figure 1A) . In all parts, male and female Ldlr weeks. In Part 3, the same four treatment groups were also treated for 8 weeks, but this time beginning at age 24 weeks and ending at 32 weeks. Of the animals in each group, 7 to 12 were analyzed for aortic en face and aortic root histology; the remaining animals were analyzed for aortic lipids. Plasma from all animals was saved for measurement of cholesterol and TG.
Aortic and Plasma Lipid Analysis
After the in vivo treatment phase, mice were euthanized with carbon dioxide, and blood was immediately collected from the vena cava into syringes rinsed with 0.5 M EDTA. Plasma was prepared via centrifugation at 850 ×g for 15 minutes at 4°C and stored at -80°C until analysis. Levels of total cholesterol (TC) and TG were determined on an automated Roche P Module Clinical Chemistry Analyzer (Roche Diagnostics, Indianapolis, Indiana).
Aortic lipid content was determined as described in a published report (20) . Briefly, after mice were euthanized and blood collected, the vasculature was perfused through the left ventricle with cold PBS supplemented with 5 mM EDTA. A section of aorta from the aortic root to the right renal artery was used for biochemical determination of cholesterol after being cleaned of adventitious fat. Total and free cholesterol (FC) were determined by an enzymatic fluorometric assay, and cholesterol ester (CE) was calculated as the difference between TC and FC.
Aorta En Face Analysis
En face analysis was performed according to previously published procedures (21) .
Briefly, after euthanasia and blood collection, mice were perfused with PBS through the left ventricle for 3 to 5 minutes, and aortas (from the point where the aorta exits the top of the heart to the iliac bifurcation) were collected, cleaned of adventitious fat, opened longitudinally, and placed in 10% formalin for up to 10 days until the time of Sudan IV staining. To prepare for the Sudan IV staining, the aortas were rinsed in PBS for 5 minutes and in 1 ml of 70% ethanol for 3 minutes, followed by gentle mixing in 70% ethanol two more times. The aortas were then immersed in 1 ml of 0.5% Sudan IV in a solution of ethanol:acetone:water (35:50:15) for 8 minutes, followed by rocking. The aortas were destained in 1 ml of 80% ethanol for 3 minutes by guest, on October 22, 2017 www.jlr.org Downloaded from twice and washed with PBS twice. The Sudan IV-stained aorta image was captured with a digital camera and analyzed with Image-Pro Plus software (Media Cybernetics, Inc., Bethesda, Maryland) to quantify Sudan IV stained surface area. Imaging and analysis were performed by a blinded operator.
Aortic Root Histomorphometric Analysis
After removal of the aortas as described above, the intact heart was removed and transected through a plane perpendicular to the aorta. The section containing the aortic root was placed in a standard cryomold, covered with OCT cryo-embedding media and immediately frozen. The whole specimen was cut in 8-µm sections, and every 4 th section was processed for hematoxylin and eosin staining. The area (in µm 2 ) of atherosclerotic lesions was then measured on digital images of the slides using computer based image analysis. Concurrent with image acquisition, the position of the distal end of the aortic valves was determined by a human operator on the basis of direct observation. This point was arbitrarily defined as zero microns.
Lesion volume in the 300 µm of aorta distal to the zero point was calculated as the summation of the lesion area times the section thickness for all the sections in 300 µm.
Statistical Methods
Comparisons between treatment groups were made using two-sample t-tests, using the WelchSatterthwaite method to avoid assuming equal variances. A two-sided P-value of less than 0.05 was required to call a difference statistically significant. No multiplicity adjustments were made to P-values. 
Results
Genetic Knockdown of DP1 in
Characterization of L-655, a selective DP1 antagonist
The affinity of L-655 for murine DP2, murine and human DP1, and TP indicated that L-655 binds more tightly to DP1 than to TP and murine DP2 ( Table 1) . L-655 also inhibited PGD 2 -induced cAMP formation in human platelet-rich plasma (PRP) with an IC50 value of 2.51  0.76 nM (n=13). In comparison, in human PRP, L-655 inhibited U46619 (1.36 µM)-induced platelet aggregation in a dose-dependent manner, with a mean IC 50  SD of 19.4  8.6 µM, indicating a high degree of selectivity for DP1 over TP (19) . In addition, U46619 demonstrated >400× selectivity of binding over EP1, EP2, EP3, EP4, FP, and IP receptors (19) . (Figure 3) . At doses of L-655 ≥100 ppm, trough afternoon plasma levels completely blocked PGD 2 -induced vasodilation, whereas morning peak levels had no off target effects in blocking induction of cutaneous vasoconstriction by the TP agonist U44619 (Figures 3 and 4) . In comparison, a 2 mg/kg dose of the TP antagonist SQ-29548 completely blocked the vasoconstriction in this model. The finding that vasodilation was blocked ~7 hours after drug-containing chow had been removed suggests that DP1 antagonism occurs throughout the day using this route of administration. Conversely, no evidence for TP antagonism was observed at any dose of L-655 tested (Figures 3 and 4) , including a dose of 1000 ppm that resulted in high plasma levels of this compound (5.06 ± 1.14 µM, data not shown).
Given that L-655 had high selectivity between functional DP1 and TP antagonism in ApoE Table S1 ); therefore, results from these studies are presented here and summarized in Table 2 . Note that the presence of nicotinic acid did not alter the plasma levels of L-655 (Table S1) , which were comparable to levels obtained in the dose finding study (Figure 3) .
Two studies used only male mice, while the third included both males and females ( Table 2; Table S2 ). Nicotinic acid alone reduced aortic CE and total aortic cholesterol ( Figure   5 ) compared with vehicle; the reduction was statistically significant in two of three studies ( Table 2) . L-655 alone produced statistically significant reductions in aortic CE ( Table 2) , TC and FC ( Table 2; Table S2 ) in female mice at a dose of 100 ppm. An analogous beneficial effect by L-655 was not induced in male mice suggesting a gender specific effect. In two studies, CE was similar or significantly less in the nicotinic acid/L-655 combination group compared with the nicotinic acid-only group ( Table 2) . In summary, L-655 produces a neutral to beneficial by guest, on October 22, 2017 www.jlr.org Downloaded from effect on aortic CE and does not attenuate the anti-athero effects of nicotinic acid ( Table 2) . Similar patterns were observed for aortic TC and FC (Table S2 ).
In the one study that included histologic assessments of aortic lesions (Table S2) , there were no significant differences between treatment groups for male mice, but female mice receiving L-655 plus nicotinic acid had significantly smaller lesions than the vehicle-only group (-20%, P = 0.045) or the niacin only group (-22%, P = 0.021).
In the same study (Study 3), L-655, with or without nicotinic acid, caused statistically significant increases of 17% to 25% in plasma TG levels in female mice but not in males.
Conversely, in male mice there was a significant 16% increase in plasma cholesterol when L-655 was combined with nicotinic acid, compared with nicotinic acid alone, but it was not significant in females. In females there was also a significant decrease in plasma cholesterol with L-655 alone (Table S2) . Table S4 ). In female mice, L-655 treatment resulted in 1.2-to 1.3-fold increases compared to vehicle in aortic lipids, and plasma cholesterol was significantly higher, by 7%. In males, aortic lesions were significantly higher with L-655 than with vehicle, by 1.5-to 5.1-fold.
Effects of L-655 ± nicotinic acid in Ldlr
However, after 16 and 24 weeks of treatment, there were no significant differences between Table S5 ). Aortic CE, FC, and TC significantly decreased both with nicotinic acid treatment alone and with the nicotinic acid/L-655 combination in males, but only with the nicotinic acid/L-655 combination in females ( Figure 8B ; Table S5 ).
Statistically significant reductions in % aortic lesion area, as measured by en face, were observed with treatment by nicotinic acid alone or in combination with L-655 in female but not male mice ( Figure 8C, Figure 9 , Table S5 ). Moreover, the nicotinic acid/L-655 combination, although not nicotinic acid alone, significantly decreased lesion area of the aortic root, as measured by histology, in females only (Table S5 ).
In part 3 of the Ldlr
-/-mouse study, examining 8 weeks of drug treatment that occurred between 24 and 32 weeks of age (Table S6) and other mouse models do not provide consistent responses for several endpoints, relative to one another and to humans (23, 25, 26) . Given these differences, caution must be exercised in the interpretation of data from murine models of disease. Nevertheless, these studies provide important mechanistic insight into atherosclerosis.
Whereas the effects of nicotinic acid on circulating lipids and lipoprotein particles have been well studied both clinically and in multiple preclinical species (1, 11, 12, 27) , few studies in preclinical species address the potential effect of nicotinic acid on plaque. In an 8-week study of male rabbits on a cholesterol-enriched (2% w/w) diet, the addition of nicotinic acid (0.4% w/w) reduced serum, liver, and aortic cholesterol (by 60%, 77%, and 64%, respectively) compared to a cholesterol diet alone (28). Nicotinic acid has also been studied in high-fat fed ApoE -/-mice (29, 30) . In that study, nicotinic acid admixed in chow (0.5% w/w) had no effect on plasma TG or by guest, on October 22, 2017 www.jlr.org Downloaded from HDL-C, nor did it affect atherosclerosis as measured by histologic and morphometric analysis of aortic lesions. Given that relatively high doses of nicotinic acid were required to alter plasma lipids in other studies (e.g., 1% in the study employing CETP transgenic mice above (31) and 3% in this work), it is very likely that a nicotinic acid dose of 0.5% w/w is not sufficient to impact plasma or aortic lipids.
In our studies in ApoE by approximately 20% to 30%. Also notable was that both strains of mice, particularly on a Western diet, were prone to developing skin lesions, which were exacerbated by fighting of cage mates. We eliminated animals with large or unhealed lesions because we have found that the presence of these skin lesions is associated with decreased plaque volume (K Cheng, unpublished data), presumably because of the immune responses generated. Mice with small skin lesions that had healed over may have been included; however, an attempt was made to closely monitor the mice across the duration of the experiments to minimize this possible variable.
However, in both models this dose of nicotinic acid tended to have smaller and less statistically significant effects on aortic lesions as compared with aortic lipids. A caveat to this comparison is the use of measurement techniques; specifically, a greater number of samples were used when studying aortic lipids by the biochemical method as compared with aortic lesions, which were measured by en face staining or histology. Historically, en face analysis has been most commonly used in the field to visually assess aortic lesions. Although en face provides detailed spatial information about the lesion location, it cannot delineate the three dimensional structure of the lesion as provided by histological assessment. Variability in these studies may arise from multiple sources, including the relatively short half-life of nicotinic acid which is administered in the feed. While niacin effects were comparable across males and females, there may be a slight gender effect with L-655 treatment alone. However, while statistical significance was met in one gender (females) and not the other (males), in general, the directionality of changes was similar for both genders. There were some anomalous gender-specific effects of L-655 on TGs and plasma cholesterol levels in female and male ApoE -/-mice; however, similar effects were not seen in Ldlr -/-mice. Given that the mice were prone to developing skin lesions, as discussed in the methods section, despite our efforts to eliminate animals with lesions, there could have been immune responses from mice with transient lesions which could have subsequently led to sporadic effects on decreased plaque volume.
There has been no reported direct link between DP1 biology and cardiovascular risk; nevertheless, in vitro data have indirectly suggested that DP1 antagonism in platelets could promote platelet aggregation and be pro-atherogenic (22) . Specifically, in vitro studies have shown that PGD 2 inhibits platelet aggregation, and platelet activation results in the release of PGD 2 . It has been speculated that antagonism of DP1 could block the ability of endogenous PGD 2 to inhibit further platelet aggregation and thereby may indirectly enhance the reactivity of platelets. However, several clinical studies have indicated that treatment with the DP1 antagonist laropiprant has no platelet aggregatory effect; in fact, a transient and mild increase in bleeding time has been reported (32) (33) (34) . One caveat in interpreting this observation is that laropiprant has been shown to antagonize both DP1 and TP in humans (32) (33) (34) , unlike the DP1-specific antagonist L-655 used in this mouse work. Therefore, it is likely that the mild anti-platelet effects in humans are a result of TP antagonism and theoretically represent a net effect of antagonizing both DP1 and TP on platelets. As such, the DP1-and TP-specific effects on platelets cannot be teased out from cited clinical studies of laropiprant.
In this work, in vivo dose selection of the DP1 antagonist L-655 (that was 20-fold more selective for DP1 over TP binding in vitro) was made such that trough afternoon plasma levels were sufficient to completely block PGD 2 -induced vasodilation (a measure of DP1-specific activity), while morning peak levels had no off target effects in blocking TP-induced vasoconstriction. Assuming that vasodilation and vasoconstriction were reasonable measures of all DP1-specific and TP-specific activity, the DP1 antagonist had no consistent or sustained effects on multiple measures of atherosclerosis. In agreement with findings of others (22), we have observed that mouse platelets do not respond to PGD 2 (as measured by cAMP production) but do respond to forskolin and iloprost treatment, suggesting very low or undetectable levels of murine DP1 expression in mouse platelets. Therefore, the overall lack of effects of L-655 on atherosclerotic measures in mice reported in this work does not necessarily apply to DP1 antagonism of human platelets and the potential effect on atherosclerosis in the clinic. However, clinical treatment with large amounts of PGD 2 that engage the DP1 receptor did not reduce bleeding times, supporting the hypothesis that engagement of the DP1 receptor does not promote pro-aggregatory platelet effects in humans (35) (36) (37) .
In summary, the present work presents a comprehensive analysis of the effects of DP1 blockade (genetic and pharmacologic) on multiple endpoints of atherosclerosis in mice. Despite the limitations of using mouse models, the data indicate a lack of consistent or sustained effects of DP1-specific antagonism on atherosclerosis both in the presence and absence of treatment with nicotinic acid, a commonly used lipid-altering agent with a mechanism of action that is weeks of age) lowers plasma and aortic cholesterols; however, L-655 had no effect on either measure ± nicotinic acid. (B) and has no effect on aortic lesions as measured en face (C). L-655 alone has no effect and does not alter the effects of nicotinic acid. by guest, on October 22, 2017 
